Evaluation of echogenicity of the heart in Kawasaki disease

Hazumu Nagata, Kenichiro Yamamura, Kiyoshi Uike, Yasutaka Nakashima, Yuichiro Hirata, Eiji Morihana, Yumi Mizuno, Shiro Ishikawa, Toshiro Hara

Research output: Contribution to journalArticle

2 Citations (Scopus)

Abstract

Pathologic studies of the heart in patients with Kawasaki disease (KD) revealed vasculitis, valvulitis, myocarditis, and pericarditis. However, there have been no studies on the quantitative determination of multi-site echogenicity of the heart in KD patients. It is also undetermined whether the degree of echogenicity of each site of the heart in patients with KD might be related to the response to intravenous immunoglobulin (IVIG) treatment. In 81 KD patients and 30 control subjects, we prospectively analyzed echogenicity of the heart. Echogenicity was measured in four sites: coronary artery wall (CAW), mitral valve (MV), papillary muscle (PM), and ascending aortic wall (AAo wall) by the calibrated integrated backscatters (cIBs). The cIB values of all measurement sites at acute phase in KD patients were significantly higher than those in control subjects (KD patients vs control subjects; CAW, 19.8±6.2 dB vs 14.5±2.0 dB, p<0.05; MV, 23.3±5.3 dB vs 16.0±3.3 dB, p<0.05; PM, 22.4±5.1 dB vs 12.7±1.9 dB, p<0.05; AAo wall, 25.3±5.6 dB vs 18.3±3.4 dB, p<0.05). The cIB values of CAW at the acute phase in IVIG nonresponders were significantly higher than those in responders. Conclusion: Echogenicity of the heart in KD patients at the acute phase increased not only in the coronary artery wall but also in other parts of the heart. Echogenicity of CAW might be helpful in determining the unresponsiveness of IVIG treatment.

Original languageEnglish
Pages (from-to)1089-1093
Number of pages5
JournalEuropean Journal of Pediatrics
Volume173
Issue number8
DOIs
Publication statusPublished - Jan 1 2014

Fingerprint

Mucocutaneous Lymph Node Syndrome
Coronary Vessels
Intravenous Immunoglobulins
Papillary Muscles
Mitral Valve
Pericarditis
Myocarditis
Vasculitis
Therapeutics

All Science Journal Classification (ASJC) codes

  • Pediatrics, Perinatology, and Child Health

Cite this

Evaluation of echogenicity of the heart in Kawasaki disease. / Nagata, Hazumu; Yamamura, Kenichiro; Uike, Kiyoshi; Nakashima, Yasutaka; Hirata, Yuichiro; Morihana, Eiji; Mizuno, Yumi; Ishikawa, Shiro; Hara, Toshiro.

In: European Journal of Pediatrics, Vol. 173, No. 8, 01.01.2014, p. 1089-1093.

Research output: Contribution to journalArticle

Nagata, H, Yamamura, K, Uike, K, Nakashima, Y, Hirata, Y, Morihana, E, Mizuno, Y, Ishikawa, S & Hara, T 2014, 'Evaluation of echogenicity of the heart in Kawasaki disease', European Journal of Pediatrics, vol. 173, no. 8, pp. 1089-1093. https://doi.org/10.1007/s00431-014-2296-4
Nagata, Hazumu ; Yamamura, Kenichiro ; Uike, Kiyoshi ; Nakashima, Yasutaka ; Hirata, Yuichiro ; Morihana, Eiji ; Mizuno, Yumi ; Ishikawa, Shiro ; Hara, Toshiro. / Evaluation of echogenicity of the heart in Kawasaki disease. In: European Journal of Pediatrics. 2014 ; Vol. 173, No. 8. pp. 1089-1093.
@article{294d6e2156c44a39837e69b659471464,
title = "Evaluation of echogenicity of the heart in Kawasaki disease",
abstract = "Pathologic studies of the heart in patients with Kawasaki disease (KD) revealed vasculitis, valvulitis, myocarditis, and pericarditis. However, there have been no studies on the quantitative determination of multi-site echogenicity of the heart in KD patients. It is also undetermined whether the degree of echogenicity of each site of the heart in patients with KD might be related to the response to intravenous immunoglobulin (IVIG) treatment. In 81 KD patients and 30 control subjects, we prospectively analyzed echogenicity of the heart. Echogenicity was measured in four sites: coronary artery wall (CAW), mitral valve (MV), papillary muscle (PM), and ascending aortic wall (AAo wall) by the calibrated integrated backscatters (cIBs). The cIB values of all measurement sites at acute phase in KD patients were significantly higher than those in control subjects (KD patients vs control subjects; CAW, 19.8±6.2 dB vs 14.5±2.0 dB, p<0.05; MV, 23.3±5.3 dB vs 16.0±3.3 dB, p<0.05; PM, 22.4±5.1 dB vs 12.7±1.9 dB, p<0.05; AAo wall, 25.3±5.6 dB vs 18.3±3.4 dB, p<0.05). The cIB values of CAW at the acute phase in IVIG nonresponders were significantly higher than those in responders. Conclusion: Echogenicity of the heart in KD patients at the acute phase increased not only in the coronary artery wall but also in other parts of the heart. Echogenicity of CAW might be helpful in determining the unresponsiveness of IVIG treatment.",
author = "Hazumu Nagata and Kenichiro Yamamura and Kiyoshi Uike and Yasutaka Nakashima and Yuichiro Hirata and Eiji Morihana and Yumi Mizuno and Shiro Ishikawa and Toshiro Hara",
year = "2014",
month = "1",
day = "1",
doi = "10.1007/s00431-014-2296-4",
language = "English",
volume = "173",
pages = "1089--1093",
journal = "European Journal of Pediatrics",
issn = "0340-6199",
publisher = "Springer Verlag",
number = "8",

}

TY - JOUR

T1 - Evaluation of echogenicity of the heart in Kawasaki disease

AU - Nagata, Hazumu

AU - Yamamura, Kenichiro

AU - Uike, Kiyoshi

AU - Nakashima, Yasutaka

AU - Hirata, Yuichiro

AU - Morihana, Eiji

AU - Mizuno, Yumi

AU - Ishikawa, Shiro

AU - Hara, Toshiro

PY - 2014/1/1

Y1 - 2014/1/1

N2 - Pathologic studies of the heart in patients with Kawasaki disease (KD) revealed vasculitis, valvulitis, myocarditis, and pericarditis. However, there have been no studies on the quantitative determination of multi-site echogenicity of the heart in KD patients. It is also undetermined whether the degree of echogenicity of each site of the heart in patients with KD might be related to the response to intravenous immunoglobulin (IVIG) treatment. In 81 KD patients and 30 control subjects, we prospectively analyzed echogenicity of the heart. Echogenicity was measured in four sites: coronary artery wall (CAW), mitral valve (MV), papillary muscle (PM), and ascending aortic wall (AAo wall) by the calibrated integrated backscatters (cIBs). The cIB values of all measurement sites at acute phase in KD patients were significantly higher than those in control subjects (KD patients vs control subjects; CAW, 19.8±6.2 dB vs 14.5±2.0 dB, p<0.05; MV, 23.3±5.3 dB vs 16.0±3.3 dB, p<0.05; PM, 22.4±5.1 dB vs 12.7±1.9 dB, p<0.05; AAo wall, 25.3±5.6 dB vs 18.3±3.4 dB, p<0.05). The cIB values of CAW at the acute phase in IVIG nonresponders were significantly higher than those in responders. Conclusion: Echogenicity of the heart in KD patients at the acute phase increased not only in the coronary artery wall but also in other parts of the heart. Echogenicity of CAW might be helpful in determining the unresponsiveness of IVIG treatment.

AB - Pathologic studies of the heart in patients with Kawasaki disease (KD) revealed vasculitis, valvulitis, myocarditis, and pericarditis. However, there have been no studies on the quantitative determination of multi-site echogenicity of the heart in KD patients. It is also undetermined whether the degree of echogenicity of each site of the heart in patients with KD might be related to the response to intravenous immunoglobulin (IVIG) treatment. In 81 KD patients and 30 control subjects, we prospectively analyzed echogenicity of the heart. Echogenicity was measured in four sites: coronary artery wall (CAW), mitral valve (MV), papillary muscle (PM), and ascending aortic wall (AAo wall) by the calibrated integrated backscatters (cIBs). The cIB values of all measurement sites at acute phase in KD patients were significantly higher than those in control subjects (KD patients vs control subjects; CAW, 19.8±6.2 dB vs 14.5±2.0 dB, p<0.05; MV, 23.3±5.3 dB vs 16.0±3.3 dB, p<0.05; PM, 22.4±5.1 dB vs 12.7±1.9 dB, p<0.05; AAo wall, 25.3±5.6 dB vs 18.3±3.4 dB, p<0.05). The cIB values of CAW at the acute phase in IVIG nonresponders were significantly higher than those in responders. Conclusion: Echogenicity of the heart in KD patients at the acute phase increased not only in the coronary artery wall but also in other parts of the heart. Echogenicity of CAW might be helpful in determining the unresponsiveness of IVIG treatment.

UR - http://www.scopus.com/inward/record.url?scp=84904413470&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=84904413470&partnerID=8YFLogxK

U2 - 10.1007/s00431-014-2296-4

DO - 10.1007/s00431-014-2296-4

M3 - Article

C2 - 24659312

AN - SCOPUS:84904413470

VL - 173

SP - 1089

EP - 1093

JO - European Journal of Pediatrics

JF - European Journal of Pediatrics

SN - 0340-6199

IS - 8

ER -